Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elevation Oncology (ELEV – Research Report) and Minerva Surgical (UTRS – Research Report).
Elevation Oncology (ELEV)
Elevation Oncology received a Hold rating from J.P. Morgan analyst Anupam Rama yesterday. The company’s shares closed last Tuesday at $1.17, close to its 52-week low of $1.02.
According to TipRanks.com, Rama is a 3-star analyst with an average return of
Elevation Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
See today’s best-performing stocks on TipRanks >>
Minerva Surgical (UTRS)
Minerva Surgical received a Sell rating from J.P. Morgan analyst Robbie Marcus yesterday. The company’s shares closed last Tuesday at $1.43, close to its 52-week low of $1.26.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Minerva Surgical with a $5.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ELEV:
- Analysts Offer Insights on Consumer Goods Companies: Electrolux AB (OtherELRXF), Shift Technologies (SFT) and Hyzon Motors (HYZN)
- Analysts Conflicted on These Financial Names: Challenger Limited (OtherCFIGF), M&G Plc (OtherMGPUF) and ABN AMRO Bank (OtherAAVMY)
- Analysts Offer Insights on Technology Companies: Alarm (ALRM), Appen Ltd. (OtherAPPEF) and Berkeley Lights (BLI)
- AbSci (ABSI) was downgraded to a Sell Rating at J.P. Morgan
- Singular Genomics Systems (OMIC) was downgraded to a Hold Rating at J.P. Morgan
